LEO Pharma Open Innovation

IL-17 release from primary human PBMC

This open innovation assay is being developed for psoriasis to asses IL-17 release from human primary PBMC. 

Brief background

The cytokine IL-17 is a main driver of psoriasis pathophysiology and can be produced by several cells including human Peripheral Blood Mononuclear Cells (PBMC). This open innovation assay is currently being developed with the aim of establishing a simple, robust and predictive model for IL-17 release. Primary human PBMC are stimulated by CD3 and CD28 activation and IL-17, IFN-gamma and cell viability is measured at the end of the incubation with test compound.